Incyte’s pemigatinib gets FDA priority review for cholangiocarcinoma
Incyte is seeking approval of pemigatinib for cholangiocarcinoma on the basis of data from the phase 2 FIGHT-202…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Nov 19
Incyte is seeking approval of pemigatinib for cholangiocarcinoma on the basis of data from the phase 2 FIGHT-202…
26 Nov 19
Risdiplam is an orally administered liquid, designed to increase and sustain SMN protein levels both in the central…
21 Nov 19
GIVLAARI is an RNAi therapeutic designed to target aminolevulinic acid synthase 1 (ALAS1) for the treatment of adults…
20 Nov 19
Daratumumab is a biologic intended to target CD38, a surface protein that is highly expressed across multiple myeloma…
18 Nov 19
The study has reached the primary endpoint and has shown consistent safety results of the individual medicines with…
15 Nov 19
AstraZeneca and MSD’s selumetinib would become the first medicine indicated for the treatment of paediatric patients with NF1…
06 Nov 19
Ziextenzo is approved for treating patients with non-myeloid malignancies, under myelosuppressive anti-cancer drugs, and with an incidence of…
31 Oct 19
The EMA has granted Accelerated Assessment, and the Committee for Medicinal Products for Human Use (CHMP) is currently…
29 Oct 19
The EC approval for the combination treatment is based on the Phase III JAVELIN Renal 101 study, which…
28 Oct 19
Astellas has secured the US and Japan regulatory approvals in 2018 for gilteritinib for the treatment of patients…